Mylan launches first bioequivalent alternative to Advair Diskus in Canada
![](/46/pdcnewsitem/08/25/29/SC1703_WixelaInhub_2017_400.jpg)
Myland Pharmaceuticals' Wixela Inhub.
Appropriate asthma and COPD patients provided with a "more affordable alternative to appropriate".
Mylan Pharmaceuticals has launched Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP) — the first available bioequivalent alternative to GSK's Advair Diskus in Canada.
Advair Diskus is a leading treatment for asthma and chronic obstructive pulmonary disease (COPD) management. According to IQVIA, it had Canadian sales of $113.9 million for the 12 months ending 31 December 2019.
Wixela Inhub is a dry powder inhaler and is the result of $700 million investment worldwide, including an extensive research and development program. It was approved by Health Canada in January for the twice-daily maintenance treatment of asthma in patients age 4 and older not adequately controlled on long-term asthma control medications or whose disease warrants initiation of treatment with both inhaled corticosteroids and long-acting beta2-agonists; or maintenance treatment of COPD.
For asthma patients, Wixela Inhub is available in 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg strengths, whereas for COPD patients, it is available in 250 mcg/50 mcg and 500 mcg/50 mcg strengths.
With today's launch in Canada, Mylan Canada Country Manager David Simpson commented: "We are pleased to expand access to this important medicine by providing a more affordable alternative to appropriate asthma and COPD patients."
![Mylan Laboratories Limited](https://www.cphi-online.com/c246364th_S-comp246364.jpg)
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance